Is pancreatic cancer palliatable? A national study by Ragulin Coyne, Elizaveta et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Research Retreat 
2012 UMass Center for Clinical and 
Translational Science Research Retreat 
May 22nd, 4:30 PM - 6:00 PM 
Is pancreatic cancer palliatable? A national study 
Elizaveta Ragulin Coyne 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat 
 Part of the Neoplasms Commons, Oncology Commons, and the Surgery Commons 
Ragulin Coyne E, Smith JK, Witkowski ER, Ng SC, McDade TP, Shah SA, Tseng JF. (2012). Is pancreatic 
cancer palliatable? A national study. UMass Center for Clinical and Translational Science Research 
Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2012/posters/54 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
1 
 
IS PANCREATIC CANCER PALLIATABLE?  A NATIONAL STUDY 
 
Elizaveta Ragulin Coyne1 MD MHS, Jillian Smith K1 MD MPH, Elan R. Witkowski1 MD, Sing-Chau Ng1 MS, 
Theodore McDade1 MD, Shimul A. Shah1 MD, Jennifer F Tseng2 MD. 
 
1University of Massachusetts Medical School, Department of Surgery, Surgical Outcomes Analysis & 
Research (SOAR), Worcester, MA; 2Department of Surgery, Beth Israel Deaconess Medical Center, 
Harvard Medical School, Boston, MA 
 
Contact: RagulinE@umassmemorial.org 
 
 
Background
 
:  Pancreatic cancer is frequently diagnosed at advanced stages where potentially curative 
resection is no longer possible.  Palliative procedures can be performed; however, results on a national 
level are unknown.  This study examines pancreatic cancer patients who underwent potentially palliative 
procedures including gastric bypass, biliary bypass surgery, celiac block, biliary stent, gastrostomy or 
jejunostomy, and examines post-intervention complications and 30-day mortality. 
Methods
 
:  SEER-Medicare 1991-2005 was used to identify patients with Stage 3-4 pancreatic cancer.  
Complication rates were calculated including post-op infection, myocardial infarction, aspiration 
pneumonia, DVT/PE, pulmonary compromise, gastric bleed, acute renal failure, and reoperation.  
Kaplan-Meier survival analysis was performed.  Finally, Cox proportional hazards modeling was used to 
control for the effects of age, sex, race, stage, and resection. 
Results
 
:  Of 22,314 pancreatic cancer patients, 858 (3.9%) patients were Stage 3, and 11,149 (50.0%) 
stage 4.  Post-procedure median survival for all patients is approximately two months, with longest 
survival for biliary bypass patients (3.2mo, 95% CI(2.9-3.7), and lowest survival for jejunostomy 1.3 mo 
(1.2-1.5) and gastrostomy 1.5 mo (1.4-1.8).  Post-
procedure 30-day mortality was highest for 
gastrostomy patients at 41.5%; followed by 
jejunostomy (39.1%), celiac plexus block (30.0%), 
gastric bypass (23.8%), biliary bypass (17.8%), and 
biliary stent (21.2%).  The rate of complications 
averaged 40%, with highest rate for gastrostomy 
(47.4%) and gastric bypass (45.3%) and lowest for 
celiac plexus block (29.3%).  Stage 4 disease was an 
independent predictor of death for patients undergoing five out of six procedures. 
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Conclusion:  We found that morbidity and mortality of palliative procedures in unresectable pancreatic 
cancer is high, especially in stage 4 patients.  Further studies need to be conducted to identify patients 
who will have sufficient expected post-procedure survival to benefit from these palliative interventions. 
